

September 7, 2016



# Citius Pharmaceuticals to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

CRANFORD, N.J., Sept. 7, 2016 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC QB: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that its Chairman, Len Mazur, will present at the Rodman & Renshaw 18<sup>th</sup> Annual Global Investment Conference. The Conference will be held on September 11-13, 2016 at the Lotte New York Palace Hotel, New York City.

Event: Rodman & Renshaw 18<sup>th</sup> Annual Global Investment Conference

Location: Lotte New York Palace Hotel

Date: Tuesday, September 13, 2016

Time: 5:05 PM (EST) in Adams Room (4<sup>th</sup> Floor)

Leonard Mazur, Chairman of Citius, will deliver the Company's corporate presentation and discuss recent business highlights. Mr. Mazur will also be available for one-on-one meetings. To arrange a meeting with management, please contact Andrew Scott at [ascott@citiuspharma.com](mailto:ascott@citiuspharma.com). Please visit this [link](#) to schedule a one-on-one meeting directly.

## About Rodman & Renshaw Conferences, LLC

The Rodman & Renshaw 18th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, is being held on September 11 – 13, 2016 at the Lotte New York Palace Hotel in New York City. Approximately 300 companies will be presenting their businesses to an audience of approximately 2,000 attendees. The conference will focus on tracks dedicated to Healthcare; Natural Resources; Technology; Media and telecommunications; Cleantech. This year's conference will bring growth companies together with a vast audience and strategic investors. In addition to corporate presentations, Rodman facilitates one-on-one investor meetings and provides platforms for engaged Q&A sessions and daily networking opportunities.

## About Citius Pharmaceuticals, Inc.

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. We focus on developing products that have intellectual property protection and competitive

advantages to existing therapeutic approaches. [www.citiuspharma.com](http://www.citiuspharma.com)

## **Safe Harbor**

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

For additional information, please contact:

Andrew Scott  
Vice President, Corporate Development  
646-522-8410; [ascott@citiuspharma.com](mailto:ascott@citiuspharma.com)

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-rodman--renshaw-18th-annual-global-investment-conference-300323865.html>

SOURCE Citius Pharmaceuticals, Inc.